Alcoholic liver disease: Role of cytokines

Biomolecules

Volumn 5, Issue 3, 2015, Pages 2023-2034

  Neuman, Manuela G ^a   Maor, Yaakov ^b   Nanau, Radu M ^a   Melzer, Ehud ^b   Mell, Haim ^c   Opris, Mihai ^a,d   Cohen, Lawrence ^a   Malnick, Stephen ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c Israel Anti Drug Authority   (Israel)

^d Casa de Ajutor Reciproc   (Romania)

Author keywords

Alcoholic liver disease; Hepatocellular carcinoma; Lipopolysaccharide; Toll like receptor; Transforming growth factor; Tumor necrosis factor

Indexed keywords

C REACTIVE PROTEIN; CXCL9 CHEMOKINE; CYTOKINE; INTERFERON; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ALCOHOL LIVER DISEASE; CYTOKINE RESPONSE; DISEASE ASSOCIATION; DISEASE COURSE; FIBROGENESIS; HUMAN; IMMUNE SYSTEM; INFLAMMATION; LIVER CELL CARCINOMA; LIVER FIBROSIS; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; STEATOSIS; ALCOHOLISM; METABOLISM;

ALCOHOLISM; CYTOKINES; HUMANS; LIPOPOLYSACCHARIDES; LIVER DISEASES, ALCOHOLIC;

EID: 85012073970     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom5032023     Document Type: Review

References (52)

1. Zimmerman, H.J. The evolution of alcoholic cirrhosis. Med. Clin. N. Am. 1955, 39, 249-251.
2. Neuman, M.G. Cytokines and inflamed liver. Clin. Biochem. 1999, 33, 601-605.
3. Neuman, M.G. Mechanism of alcoholic liver disease. Clin. Biochem. 2001, 34, 163-167.
4. Neuman, M.G. Cytokines in alcoholic liver. Alcohol Res. Health 2003, 27, 307-316.
5. Ishak, K.G.; Zimmerman, H.J.; Ray, M.B. Alcoholic liver disease: Pathologic, pathogenetic and clinical aspects. Alcohol Clin. Exp. Res. 1991, 15, 45-66.
6. Lefkowitch, J.H. Morphology of alcoholic liver disease. Clin. Liver Dis. 2005, 9, 37-53.
7. O'Shea, R.S.; Dasarathy, S.; McCullough, A.J. Alcoholic liver disease. Hepatology 2010, 51, 307-28.
8. Pares, A.; Caballeria, J.; Bruguera, M.; Torres, M.; Rodes, J. Histologic course of alcoholic hepatitis: Influence of abstinence, sex and extent of hepatic damage. J. Hepatol. 1986, 2, 33-42.
9. Decker, K. Biologically active products of stimulated liver macrophages (Kupffer cells). Eur. J. Biochem. 1990, 192, 245-261.
10. Neuman, M.G.; French, S.W.; French, B.A.; Seitz, H.K.; Cohen, L.B.; Mueller, S.; Osna, N.A.; Kharbanda, K.K.; Seth, D.; Bautista, A.; et al. Alcoholic and nonalcoholic steatohepatitis. Exp. Mol. Pathol. 2014, 97, 492-510.
11. Umhau, J.C.; Schwandt, M.; Solomon, M.G.; Yuan, P.; Nugent, A.; Zarate, C.A.; Drevets, W.C.; Hall, S.D.; George, D.T.; Heilig, M. Cerebrospinal fluid monocyte chemoattractant protein-1 in alcoholics: Support for a neuroinflammatory model of chronic alcoholism. Alcohol Clin. Exp. Res. 2014, 38, 1301-1306.
12. Fuster, D.; Cheng, D.M.; Quinn, E.K.; Armah, K.A.; Saitz, R.; Freiberg, M.S.; Samet, J.H.; Tsui, J.I. Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems. AIDS 2014, 28, 1059-1064.
13. Reiberger, T.; Ferlitsch, A.; Payer, B.A.; Mandorfer, M.; Heinisch, B.B.; Hayden, H.; Lammert, F.; Trauner, M.; Peck-Radosavljevic, M.; Vogelsang, H. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J. Hepatol. 2013, 58, 911-921.
14. González-Reimers, E.; Santolaria-Fernández, F.; Medina-García, J.A.; González-Pérez, J.M.; de la Vega-Prieto, M.J.; Medina-Vega, L.; Martín-González, C.; Durán-Castellón, M.C. TH-1 and TH-2 cytokines in stable chronic alcoholics. Alcohol Alcohol. 2012, 47, 390-396.
15. González-Reimers, E.; Sánchez-Pérez, M.J.; Santolaria-Fernández, F.; Abreu-González, P.; de la Vega-Prieto, M.J.; Viña-Rodríguez, J.; Alemán-Valls, M.R.; Rodríguez-Gaspar, M. Changes in cytokine levels during admission and mortality in acute alcoholic hepatitis. Alcohol 2012, 46, 433-440.
16. Mortensen, C.; Andersen, O.; Krag, A.; Bendtsen, F.; Møller, S. High-sensitivity C-reactive protein levels predict survival and are related to haemodynamics in alcoholic cirrhosis. Eur. J. Gastroenterol. Hepatol. 2012, 24, 619-626.
17. Ishikawa, M.; Uemura, M.; Matsuyama, T.; Matsumoto, M.; Ishizashi, H.; Kato, S.; Morioka, C.; Fujimoto, M.; Kojima, H.; Yoshiji, H.; et al. Potential role of enhanced cytokinemia and plasma inhibitor on the decreased activity of plasma ADAMTS13 in patients with alcoholic hepatitis: Relationship to endotoxemia. Alcohol Clin. Exp. Res. 2010, 34, S25-S33.
18. Díez-Ruiz, A.; García-Saura, P.L.; García-Ruiz, P.; González-Calvin, J.L.; Gallego-Rojo, F.; Fuchs, D. Bone mineral density, bone turnover markers and cytokines in alcohol-induced cirrhosis. Alcohol Alcohol. 2010, 45, 427-430.
19. Tung, K.H.; Huang, Y.S.; Yang, K.C.; Perng, C.L.; Lin, H.C.; Lee, S.D. Serum interleukin-12 levels in alcoholic liver disease. J. Chin. Med. Assoc. 2010, 73, 67-71.
20. Lavallard, V.J.; Bonnafous, S.; Patouraux, S.; Saint-Paul, M.C.; Rousseau, D.; Anty, R.; le Marchand-Brustel, Y.; Tran, A.; Gual, P. Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease. PLoS ONE 2011, 6, e17599.
21. Zuwała-Jagiełło, J.; Pazgan-Simon, M.; Simon, K.; Warwas, M. Advanced oxidation protein products and inflammatory markers in liver cirrhosis: A comparison between alcohol-related and HCV-related cirrhosis. Acta Biochim. Pol. 2011, 58, 59-65.
22. Friedman, S.L. Molecular regulation of hepatic fibrosis, and integrated cellular response to tissue injury. J. Biol. Chem. 2000, 275, 2247-2250.
23. Neuman, M.G.; Schmilovitz-Weiss, H.; Hilzenrat, N.; Bourliere, M.; Marcellin, P.; Trepo, C.; Mazulli, T.; Moussa, G.; Patel, A.; Baig, A.A.; et al. Markers of inflammation and fibrosis in alcoholic hepatitis and viral hepatitis C. Int. J. Hepatol. 2012, doi: 10.1155/2012/231210.
24. Sowa, J.P.; Atmaca, Ö.; Kahraman, A.; Schlattjan, M.; Lindner, M.; Sydor, S.; Scherbaum, N.; Lackner, K.; Gerken, G.; Heider, D.; et al. Non-invasive separation of alcoholic and non-alcoholic liver disease with predictive modeling. PLoS ONE 2014, 9, e101444.
25. Chatzipanagiotou, S.; Kalykaki, M.; Tzavellas, E.; Karaiskos, D.; Paparrigopoulos, T.; Liappas, A.; Nicolaou, C.; Michalopoulou, M.; Zoga, M.; Boufidou, F.; et al. Alteration of biological markers in alcohol-dependent individuals without liver disease during the detoxification therapy. In Vivo 2010, 24, 325-328.
26. Roy, N.; Mukhopadhyay, I.; Das, K.; Pandit, P.; Majumder, P.P.; Santra, A.; Datta, S.; Banerjee, S.; Chowdhury, A. Genetic variants of TNFα, IL10, IL1α, CTLA4 and TGFα1 modulate the indices of alcohol-induced liver injury in East Indian population. Gene 2012, 509, 178-188.
27. Lee, J.J.; Park, S.K.; Kwon, O.S.; Won, I.S.; Kim, D.K.; Jung, Y.K.; Ku, Y.S.; Kim, Y.S.; Choi, D.J.; Kim, J.H. Genetic polymorphism at codon 10 of the transforming growth factor-α1 gene inpatients with alcoholic liver cirrhosis. Korean J. Hepatol. 2011, 17, 37-43.
28. McClain, C.J.; Hill, D.B.; Schmidt, J.; Diehl, A.M. Cytokines and alcoholic liver disease. Semin Liver Dis. 1993, 13, 170-182.
29. Gao, B.; Xu, M. Chemokines and alcoholic hepatitis: Are chemokines good therapeutic targets? Gut 2014, 63, 1683-1684.
30. Dhanda, A.D.; Lee, R.W.; Collins, P.L.; McCune, C.A. Molecular targets in the treatment of alcoholic hepatitis. World J. Gastroenterol. 2012, 18, 5504-5513.
31. Dominguez, M.; Miquel, R.; Colmenero, J.; Moreno, M.; García-Pagán, J.C.; Bosch, J.; Arroyo, V.; Ginès, P.; Caballería, J.; Bataller, R. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology 2009, 136, 1639-1650.
32. Affò, S.; Dominguez, M.; Lozano, J.J.; Sancho-Bru, P.; Rodrigo-Torres, D.; Morales-Ibanez, O.; Moreno, M.; Millán, C.; Loaeza-del-Castillo, A.; Altamirano, J.; et al. Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut 2013, 62, 452-460.
33. Affò, S.; Morales-Ibanez, O.; Rodrigo-Torres, D.; Altamirano, J.; Blaya, D.; Dapito, D.H.; Millán, C.; Coll, M.; Caviglia, J.M.; Arroyo, V.; et al. CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. Gut 2014, 63, 1782-1792.
34. Voican, C.S.; Njiké-Nakseu, M.; Boujedidi, H.; Barri-Ova, N.; Bouchet-Delbos, L.; Agostini, H.; Maitre, S.; Prévot, S.; Cassard-Doulcier, A.M.; Naveau, S.; et al. Alcohol withdrawal alleviates adipose tissue inflammation in patients with alcoholic liver disease. Liver Int. 2015, 35, 967-978.
35. Patouraux, S.; Bonnafous, S.; Voican, C.S.; Anty, R.; Saint-Paul, M.C.; Rosenthal-Allieri, M.A.; Agostini, H.; Njike, M.; Barri-Ova, N.; Naveau, S.; et al. The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease. PLoS ONE 2012, 7, e35612.
36. Morales-Ibanez, O.; Domínguez, M.; Ki, S.H.; Marcos, M.; Chaves, J.F.; Nguyen-Khac, E.; Houchi, H.; Affò, S.; Sancho-Bru, P.; Altamirano, J.; et al. Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. Hepatology 2013, 58, 1742-1756.
37. Nischalke, H.D.; Berger, C.; Lutz, P.; Langhans, B.; Wolter, F.; Eisenhardt, M.; Krämer, B.; Kokordelis, P.; Glässner, A.; Müller, T.; et al. Influence of the CXCL1 rs4074 A allele on alcohol induced cirrhosis and HCC inpatients of European descent. PLoS ONE 2013, 8, e80848.
38. Wan, J.; Benkdane, M.; Teixeira-Clerc, F.; Bonnafous, S.; Louvet, A.; Lafdil, F.; Pecker, F.; Tran, A.; Gual, P.; Mallat, A.; et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: A protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 2014, 59, 130-142.
39. Rachakonda, V.; Gabbert, C.; Raina, A.; Li, H.; Malik, S.; DeLany, J.P.; Behari, J. Stratification of risk of death in severe acute alcoholic hepatitis using a panel of adipokines and cytokines. Alcohol Clin. Exp. Res. 2014, 38, 2712-2721.
40. Hartmann, P.; Chen, W.C.; Schnabl, B. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front. Physiol. 2012, doi:10.3389/fphys.2012.00402.
41. Bode, C.; Bode, J.C. Activation of the innate immune system and alcoholic liver disease: Effects of ethanol per se or enhanced intestinal translocation of bacterial toxins induced by ethanol? Alcohol Clin. Exp. Res. 2005, 29, S166-S171.
42. Chassaing, B.; Etienne-Mesmin, L.; Gewirtz, A.T. Microbiota-liver axis in hepatic disease. Hepatology 2014, 59, 328-339.
43. Da Silva Correia, J.; Soldau, K.; Christen, U.; Tobias, P.S.; Ulevitch, R.J. Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. Transfer from CD14 to TLR4 and MD-2. J. Biol. Chem. 2001, 276, 21129-21135.
44. Kawai, T.; Takeuchi, O.; Fujita, T.; Inoue, J.; Mühlradt, P.F.; Sato, S.; Hoshino, K.; Akira, S. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J. Immunol. 2001, 167, 5887-5894.
45. Jampana, S.C.; Khan, R. Pathogenesis of alcoholic hepatitis: Role of inflammatory signaling and oxidative stress. World J. Hepatol. 2011, 3, 114-117.
46. Chen, P.; Stärkel, P.; Turner, J.R.; Ho, S.B.; Schnabl, B. Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice. Hepatology 2015, 61, 883-894.
47. Barve, S.; Kirpich, I.A.; McClain, C.J. Tumor necrosis factor alpha-induced receptor 1 signaling in alcoholic liver disease: A gut reaction? Hepatology 2015, 61, 754-756.
48. Ceccarelli, S.; Nobili, V.; Alisi, A. Toll-like receptor-mediated signaling cascade as a regulator of the inflammation network during alcoholic liver disease. World J. Gastroenterol. 2014, 20, 16443-16451.
49. Mutlu, E.A.; Gillevet, P.M.; Rangwala, H.; Sikaroodi, M.; Naqvi, A.; Engen, P.A.; Kwasny, M.; Lau, C.K.; Keshavarzian, A. Colonic microbiome is altered in alcoholism. Am. J. Physiol. Gastrointest Liver Physiol. 2012, 302, G966-G978.
50. Markwick, L.J.; Riva, A.; Ryan, J.M.; Cooksley, H.; Palma, E.; Tranah, T.H.; Manakkat Vijay, G.K.; Vergis, N.; Thursz, M.; Evans, A.; et al. Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. Gastroenterology 2015, 148, 590-602.
51. Almeida, J.; Polvorosa, M.A.; Gonzalez-Quintela, A.; Marcos, M.; Pastor, I.; Cerceño, M.L.H.; Orfao, A.; Laso, F.J. Decreased peripheral blood CD4+/CD25+ regulatory T cells in patients with alcoholic hepatitis. Alcohol Clin. Exp. Res. 2013, 37, 1361-1369.
52. Sandahl, T.D.; Grønbaek, H.; Møller, H.J.; Støy, S.; Thomsen, K.L.; Dige, A.K.; Agnholt, J.; Hamilton-Dutoit, S.; Thiel, S.; Vilstrup, H. Hepatic macrophage activation and the LPS pathway in patients with alcoholic hepatitis: A prospective cohort study. Am. J. Gastroenterol. 2014, 109, 1749-1756.